These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 24931161)

  • 1. CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo.
    Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Corrado A; Fioravanti A; Sartini S; Orlandi P; Piaggi S; Corti A; Materazzi G; Galleri D; Ulisse S; Fontanini G; Danesi R; Da Settimo F; Miccoli P
    Mol Cell Endocrinol; 2014 Aug; 393(1-2):56-64. PubMed ID: 24931161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer.
    Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
    J Clin Endocrinol Metab; 2011 Feb; 96(2):E288-96. PubMed ID: 21147882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro.
    Ferrari SM; Fallahi P; La Motta C; Bocci G; Corrado A; Materazzi G; Galleri D; Piaggi S; Danesi R; Da Settimo F; Miccoli P; Antonelli A
    Surgery; 2014 Nov; 156(5):1167-76. PubMed ID: 25151558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
    Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
    Antonelli A; Bocci G; Fallahi P; La Motta C; Ferrari SM; Mancusi C; Fioravanti A; Di Desidero T; Sartini S; Corti A; Piaggi S; Materazzi G; Spinelli C; Fontanini G; Danesi R; Da Settimo F; Miccoli P
    J Clin Endocrinol Metab; 2014 Apr; 99(4):E572-81. PubMed ID: 24423321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
    Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Ruffilli I; Di Domenicantonio A; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Di Desidero T; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E528-36. PubMed ID: 22278419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
    Ferrari SM; La Motta C; Sartini S; Baldini E; Materazzi G; Politti U; Ruffilli I; Ulisse S; Miccoli P; Antonelli A; Fallahi P
    Mini Rev Med Chem; 2016; 16(2):86-93. PubMed ID: 26471970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
    Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
    Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
    Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
    Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice.
    Quidville V; Segond N; Tebbi A; Cohen R; Jullienne A; Lepoivre M; Lausson S
    Thyroid; 2009 Jun; 19(6):613-21. PubMed ID: 19281427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
    Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571.
    Skinner MA; Safford SD; Freemerman AJ
    Anticancer Res; 2003; 23(5A):3601-6. PubMed ID: 14666655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid.
    Yalcin M; Dyskin E; Lansing L; Bharali DJ; Mousa SS; Bridoux A; Hercbergs AH; Lin HY; Davis FB; Glinsky GV; Glinskii A; Ma J; Davis PJ; Mousa SA
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1972-80. PubMed ID: 20133461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of
    Bagheri-Yarmand R; Dadu R; Ye L; Shiny Jebaraj Y; Martinez JA; Ma J; Tarapore RS; Allen JE; Sherman SI; Williams MD; Gagel RF
    Mol Cancer Ther; 2021 Apr; 20(4):665-675. PubMed ID: 33536187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity of motesanib in a medullary thyroid cancer model.
    Coxon A; Bready J; Kaufman S; Estrada J; Osgood T; Canon J; Wang L; Radinsky R; Kendall R; Hughes P; Polverino A
    J Endocrinol Invest; 2012 Feb; 35(2):181-90. PubMed ID: 21422803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RET signals through focal adhesion kinase in medullary thyroid cancer cells.
    Panta GR; Nwariaku F; Kim LT
    Surgery; 2004 Dec; 136(6):1212-7. PubMed ID: 15657578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
    Strock CJ; Park JI; Rosen M; Dionne C; Ruggeri B; Jones-Bolin S; Denmeade SR; Ball DW; Nelkin BD
    Cancer Res; 2003 Sep; 63(17):5559-63. PubMed ID: 14500395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.
    Ezzat S; Huang P; Dackiw A; Asa SL
    Clin Cancer Res; 2005 Feb; 11(3):1336-41. PubMed ID: 15709206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates.
    Morisi R; Celano M; Tosi E; Schenone S; Navarra M; Ferretti E; Costante G; Durante C; Botta G; D'Agostino M; Brullo C; Filetti S; Botta M; Russo D
    J Endocrinol Invest; 2007 Nov; 30(10):RC31-4. PubMed ID: 18075281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium/Calmodulin-dependent protein kinase II and its endogenous inhibitor α in medullary thyroid cancer.
    Russo E; Salzano M; De Falco V; Mian C; Barollo S; Secondo A; Bifulco M; Vitale M
    Clin Cancer Res; 2014 Mar; 20(6):1513-20. PubMed ID: 24449826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.